How have Polynovo shares been performing since leaving the ASX 200?

The medical device company's shares can't seem to catch a break this week.

| More on:
A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares are edging 1.15% lower to $1.295 on Tuesday
  • While no company announcements have been made, Polynovo shares were removed from the ASX 200 on Monday
  • The quarterly rebalance forces fund managers to adjust their portfolios to adhere to operating mandates, which in turn can put buying or selling pressure on particular shares

The Polynovo Ltd (ASX: PNV) share price is heading south again today despite the company not releasing any announcements.

Since the start of the week, the medical device company's shares are down 3% to currently trade at $1.295 each.

While down 1.15% today, this isn't the case for the S&P/ASX 200 Index (ASX: XJO) which is 1.59% higher to 6,535 points at the time of writing.

Let's take a look at what is weighing down the Polynovo share price of late.

What's impacting Polynovo shares?

Besides the recent buying action by the company's board, it has been relatively quiet for Polynovo.

Its last trading update came in early April when management provided a snapshot of the company's third-quarter results.

Since then, Polynovo shares tumbled to a multi-year low of 83.5 cents before rebounding to February 2022 levels.

The share price weakness came off the back of negative investor sentiment across the ASX following fears surrounding a possible recession.

However, added to the mix is the large number of short-sellers on Polynovo's registry.

The latest short position report by the Australian Securities & Investments Commission (ASIC) reveals the level of short interest within companies.

Polynovo remains in the top 10 of short interest ASX stocks, with 10.95% of its shares being shorted by investors.

In case you aren't aware, short-selling is a common trading strategy that aims to profit from the fall in the price of a security. The goal is for an investor to borrow shares then sell them and buy them back at a lower price for a profit.

On top of this, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has fallen by 4.63% in the past week and is down 15% in 2022.

Yet perhaps the biggest selling pressure has come from Polynovo's removal from the S&P/ASX 200 Index (ASX: XJO) which took effect on Monday.

The S&P Dow Jones Indices announced changes in its quarterly rebalance earlier this month.

Polynovo's removal from the ASX 200 means that fund managers must abide by their investing mandate which permits them to only buy shares included in specific indices. It's commonplace that shares can climb or fall after being included in or excluded from a particular index.

Polynovo share price summary

While staging a small rebound from early May onwards, the Polynovo share price is down 15% year-to-date.

When looking at the past 12 months, its shares are deep in the red by 53%.

Based on today's price, Polynovo presides a market capitalisation of about $856 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »